WO2000032247A9 - Antimicrobial fabric and medical graft of the fabric - Google Patents
Antimicrobial fabric and medical graft of the fabricInfo
- Publication number
- WO2000032247A9 WO2000032247A9 PCT/US1999/027190 US9927190W WO0032247A9 WO 2000032247 A9 WO2000032247 A9 WO 2000032247A9 US 9927190 W US9927190 W US 9927190W WO 0032247 A9 WO0032247 A9 WO 0032247A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fabric
- graft
- coating material
- antimicrobial agent
- applying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates to a fabric having antimicrobial properties and a medical graft, such as a vascular graft, made of such fabric.
- a graft is a tubular type member typically used to provide a passage for fluid flow between two parts of a vein or artery that has been severed or as a bypass for diseased or deteriorated tissue.
- grafts are often used in vascular bypass applications, such as for an abdominal aortic aneurism.
- the graft can either be of natural material, taken from another part of the body of a human or an animal, or it can be of synthetic material.
- the graft is of synthetic material, it would be desirable for it to be able to inhibit the growth of bacteria in the fluid flowing in the graft or from other body parts that come into contact with the graft.
- Other medical products, such as pledgets and patches, would also desirably have the same properties.
- the present invention is directed to a graft for medical use that is made of a fabric constraining an inorganic antimicrobial agent.
- the fabric has the inorganic antimicrobial agent bonded to it, the agent preferably being a zeolite.
- the fabric fibers are preferably of Teflon or polyester.
- the fabric can be porous so as to permit tissue to grow on it with the fabric pores providing attachment sites for the tissue.
- a non-porous fabric is coated with a tissue biocompatible material, such as collagen, which also can be coated on a porous fabric.
- the present invention also is directed to an antimicrobial fabric applicable for the graft, and for other medical uses, having a coating thereon to which is bonded an antimicrobial agent, such as a zeolite.
- an antimicrobial agent such as a zeolite.
- the fabric is porous, it remains pliable and flexible. This type of fabric, which is pliable, has use for other types of medical products such as pledgets and patches.
- the fabric is held under tension in one direction and a mixture of an adherent type coating material, such as a hydrophilic polymer or silicone, is applied which covers the fabric fibers and fills the spaces between the fibers.
- an adherent type coating material such as a hydrophilic polymer or silicone
- a dusting of the antimicrobial agent is applied onto the coating material while it is still wet. This bonds the agent to the coating material.
- the fabric is then cured with a pressurized gas, such as air, to dry it. The air under pressure removes all of the matter, coating material and antimicrobial agent, from between the fibers making it porous allowing it to be pliable.
- the antimicrobial agent is mixed with the coating material, the mixture is applied to the fabric and the matter between the pores is removed by the pressurized air drying.
- the fabric will dry with the coating material and antimicrobial agent present in the pores as well as with the antimicrobial agent bonded to the fabric fibers.
- the fabric since the fabric does not have pores for tissue attachment sites it is preferred that the fabric be coated with a tissue growth promoting material, such as collagen.
- the antimicrobial agent is on the surface of the fabric bonded to the coating material and is available to provide antimicrobial action relative to fluids and body parts that come into contact with it.
- An object of the invention is to provide a medical graft of a fabric containing an inorganic antimicrobial agent.
- Another object is to provide a medical graft of a fabric containing an inorganic antimicrobial agent that is coated with a tissue compatible material.
- Yet a further object is to provide a vascular graft utilizing a porous fabric having antimicrobial properties.
- Fig. 1 is a perspective view of a base fabric
- Fig. 2 is a cross-sectional view along lines 2-2 of Fig. 1 showing application of the coating material to the fabric
- Fig. 3 is a cross-sectional view of the fabric after the antimicrobial agent has been applied
- Fig. 4 is a cross-sectional view of the finished fabric after drying
- Fig. 5 is a view of a vascular graft using the fabric of the invention.
- Fig. 5 illustrates a vascular graft 70 made with the inorganic antimicrobial fabric. While the graft illustrated is of the pleated type, such as shown in U.S. patent 5,607,464, it can be of the more conventional type that has no pleats.
- the graft 70 is of the generally overall cylindrical construction so that it can be attached between the ends of the body tissue to be connected or used as a bypass.
- the antimicrobial fabric 72 forming the graft is of one of the types described below.
- the outer surface of the graft of Fig. 5 is shown as being coated with a tissue compatible material 74 which can promote tissue growth, such as collagen.
- tissue compatible material 74 which can promote tissue growth, such as collagen.
- the collagen coating is usually used where the fabric is completely coated with the antimicrobial agent. If the graft fabric is porous, it normally is left uncoated since the presence of pores in the fabric provides sites for tissue attachment. However, a porous fabric also can be coated with collagen.
- Coated fabric that is porous Figs. 1-4 describe a porous antimicrobial fabric and method of manufacture useful for the graft and which also has other medical uses due to its pliability.
- Fig.l there a base material comprising a piece of fabric 10 of the mesh type formed by fibers 12 which are laid transverse to each other and which define spaces, or pores, 14 between the fibers.
- the fibers can be of any suitable material, for example, cotton, nylon polyester, Teflon, e-PTFE and blends of these materials.
- Teflon or polyester is preferred.
- the fabric can be either of the woven or non-woven type.
- the fabric 10 is shown by the arrows T as being able to be held under tension in both directions generally along the fabric length and width, in the directions of the cross-laid fibers, by any suitable mechanism (not shown), for example, rollers, clamps, etc..
- Fig. 2 shows the fabric piece 10 in the stage of having an coating of an adherent material 18 applied to one surface. It should be understood that the invention is applicable to performing the process on both fabric surfaces and on the sides of the fabric fibers forming the pores 14.
- the adherent coating material 18 is a biologically compatible material such as, for example, acrylic, polyurethane, silicone, latex, polyglycolic lactic acid or other biodegradable polymer, especially one that is a hydrophilic, a non-degrading polymer such as a hydrophilic polyurethane, for example TECOPHILIC which is made by Thermedics. These materials all have elastomeric properties.
- the fabric coating material 18 is applied as a mixture of a high strength RTV dispersed in a solvent, such as xylene.
- a preferred composition of the mixture is 50% RTV and 50% xylene although the ratio of the two materials can be varied. Increasing the proportion of the coating material in the mixture makes the final fabric product less pliable.
- the fabric 10 is held under tension in its lengthwise dimension.
- the coating material mixture 18 is supplied by a peristaltic pump to an ultrasonic disperser.
- the ultrasonic disperser creates a fine mist of the mixture that is blown out of the disperser by an air source, illustratively shown by reference numeral 19, to coat the fabric 10.
- the fabric preferably is coated on both surfaces.
- Fig. 3 shows the fabric 10 having been coated on one side with the coating material 18.
- the coating material 18 extends into the openings 14 between the fibers of the fabric and also coats the top of each of the fibers.
- the fabric can be cycled relative to the disperser as many times as needed. That is, the deposition of the coating material mixture on the fabric can be accomplished by applying a desired number of layers to achieve a desired thickness.
- the layers are contiguous to and mixed with each other.
- the depth of the coating material 18 on top of the fabric is selected to be between 0.01 and 50 microns, more preferably between 0.1 and 25 microns, and most preferably between 0.1 and 10 microns.
- an inorganic antimicrobial agent 20 in powdered form is applied to the coating material 18 while it is still wet.
- the fabric preferably is held under tension in both directions, that is, generally along both the fabric length and width.
- the powdered antimicrobial agent 20 becomes immersed into and bonds with the coating material layer 18 on the fabric.
- the inorganic antimicrobial agent 20 As to the inorganic antimicrobial agent 20, a number of metal ions, which are inorganic materials, have been shown to possess antibiotic activity, including silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium and thallium ions. These antibiotic metal ions are believed to exert their effects by disrupting respiration and electron transport systems upon absorption into bacterial or fungal cells. Antimicrobial metal ions of silver, gold, copper and zinc, in particular, are considered safe even for in vivo use. Antimicrobial silver ions are particularly useful for in vivo use due to the fact that they are not substantially absorbed into the body. That is, if such materials are used for the antimicrobial fabric, they should pose no hazard to the body.
- Antibiotic zeolites also are suitable as the agent. These have been prepared by replacing all or part of the ion-exchangeable ions in zeolite with ammonium ions and antibiotic metal ions, as described in U.S. Patent Nos. 4,938,958 and 4,911,898. Such zeolites have been incorporated in antibiotic resins (as shown in U.S. Patent Nos. 4,938,955 and 4,906,464) and polymer articles (U.S. Patent No. 4,775,585). Polymers including the antibiotic zeolites have been used to make refrigerators, dish washers, rice cookers, plastic film, chopping boards, vacuum bottles, plastic pails, and garbage containers.
- antibiotic zeolites include flooring, wall paper, cloth, paint, napkins, plastic automobile parts, catheters, bicycles, pens, toys, sand, and concrete. Examples of such uses are described in U.S. Patents 5,714,445; 5,697,203; 5,562,872; 5,180,585; 5,714,430; and 5,102,401. These applications involve slow release of antibiotic silver from the zeolite particles which is suitable for the antimicrobial fabric.
- Antibiotic zeolites are well-known and can be prepared for use in the present invention using known methods. These include the antibiotic zeolites disclosed, for example, in U.S. Patent Nos. 4,938,958 and 4,911,898.
- the inorganic antibiotic metal containing composition is an antibiotic metal salt.
- antibiotic metal salts include Such salts include silver iodate, silver iodide, silver nitrate, and silver oxide. Silver nitrate is preferred. These salts are particularly quick acting, as no release from ceramic particles is necessary to function antimicrobially.
- Antibiotic ceramic particles useful with the present invention include zeolites, hydroxyapatite, zirconium phosphates or other ion-exchange ceramics. Hydroxyapatite particles containing antimicrobial metals are described, e.g., in U.S. Patent No. 5,009,898. Zirconium phosphates containing antimicrobial metals are described, e.g., in U.S. Patent Nos. 5,296,238; 5,441,717; and 5,405,644.
- Zeolite is an aluminosilicate having a three dimensional skeletal structure that is represented by the formula: XM 2 /nO-Al 2 O 3 -YSiO 2 -ZH 2 O.
- M represents an ion-exchangeable ion, generally a monovalent or divalent metal ion
- n represents the atomic valency of the (metal) ion
- Y represent coefficients of metal oxide and silica respectively, and Z represents the number of water of crystallization.
- zeolites include A-type zeolites, X-type zeolites, Y-type zeolites, T-type zeolites, high-silica zeolites, sodalite, mordenite, analcite, clinoptilolite, chabazite and erionite.
- the present invention is not restricted to use of these specific zeolites.
- These ion-exchange capacities are sufficient for the zeolites to undergo ion-exchange with ammonium and antibiotic metal ions.
- the specific surface area of preferred zeolite particles is preferably at least 150 m 2 /g (anhydrous zeolite as standard) and the SiO 2 /A12O 3 mol ratio in the zeolite composition is preferably less than 14, more preferably less than 11.
- the antibiotic metal ions used in the antibiotic zeolites should be retained on the zeolite particles through an ion-exchange reaction.
- Antibiotic metal ions which are adsorbed or attached without an ion-exchange reaction exhibit a decreased bacteriocidal effect and their antibiotic effect is not long-lasting. Nevertheless, it is advantageous for imparting quick antimicrobial action to maintain a sufficient amount of surface adsorbed metal ion.
- the antibiotic metal ions tend to be converted into their oxides, hydroxides, basic salts etc. either in the micropores or on the surfaces of the zeolite and also tend to deposit there, particularly when the concentration of metal ions in the vicinity of the zeolite surface is high. Such deposition tends to adversely affect the bactericidal properties of ion-exchanged zeolite.
- a relatively low degree of ion exchange is employed to obtain superior bactericidal properties. It is believed to be required that at least a portion of the zeolite particles retain metal ions having bactericidal properties at ion-exchangeable sites of the zeolite in an amount less than the ion-exchange saturation capacity of the zeolite. In one embodiment, the zeolite employed in the present invention retains antimicrobial metal ions in an amount up to 41% of the theoretical ion-exchange capacity of the zeolite.
- Such ion-exchanged zeolite with a relatively low degree of ion-exchange may be prepared by performing ion-exchange using a metal ion solution having a low concentration as compared with solutions conventionally used for ion exchange.
- the antibiotic metal ion is preferably present in the range of from about 0.1 to 20wt.% of the zeolite.
- the zeolite contain from 0.1 to 20wt.% of silver ions and from 0.1 to 20wt.% of copper or zinc ions.
- ammonium ion can be contained in the zeolite at a concentration of about 20 wt.% or less of the zeolite, it is desirable to limit the content of ammonium ions to from 0.5 to 15 wt.%, preferably 1.5 to 5 wt.%.
- Weight% described herein is determined for materials dried at temperatures such as 110°C, 250°C or 550°C as this is the temperature employed for the preferred post- manufacturing drying process.
- a preferred antibiotic zeolite is type A zeolite containing either a combination of ion-exchanged silver, zinc, and ammonium or silver and ammonium.
- One such zeolite is manufactured by Shinegawa, Inc. under the product number AW- ION and consists of 0.6% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 2.5 ⁇ .
- Another formulation, AJ-10N consists of about 2% by weight silver ion-exchanged in Type A zeolite particles having a diameter of about 2.5 ⁇ .
- Another formulation, AW-80 contains 0.6% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about l .O ⁇ .
- Another formulation, AJ-80N consists of about 2% by weight silver ion-exchanged in Type A zeolite particles having a diameter of about l.O ⁇ . These zeolites preferably contain about between 0.5% and 25.0% by weight of ion-exchanged ammonium.
- the inorganic antimicrobial agent can be of the type designated HealthShield, which is sold by the assignee of the subject application.
- This material is basically a zeolite, this being a metal having one or the whole of the metal substituted by at least one kind of an ion exchangeable metal selected from the group consisting of Ag, Cu and Zn.
- a typical particle size for the agent is between 0.8 and 10 microns.
- the agent is dispersed on the coating material 18 in the quantity of between 0.5 and 20%) by weight, more preferably between 0.5 and 10% and most preferably between 0.5 and 5% of the matter that remains on the fabric, exclusive of the fabric. The particles adhere to the coating material while it is wet and become embedded in the coating material 18 as it dries.
- inorganic antimicrobial agents i.e., those containing silver, copper, lead, gold tin, zinc and mercury, can be used.
- each of the fabric fibers has on one surface thereof the coating material 18 in which are the embedded particles of the antimicrobial agent 20. If both surfaces of the fabric are treated, the entirety of the fabric would have the same appearance. In any case, the fabric pores 14 would be clear. This maintains fabric pliability.
- the inorganic antimicrobial is blended into the textile coating material, such as of the type described above.
- the mixture is then applied to the base fabric by a spraying process, as previously described, or by dipping.
- the fabric is preferably held under tension. This eliminates the step of dusting the fibers with the particles of the agent.
- the wet fabric is held under tension and is subjected to a blowing operation to remove matter from the fabric pores. This results in the fabric substantially retaining its porosity. Thus, the fabric will be relatively more flexible than if the pores were not clear.
- the coating materials can include, for example, acrylic, polyurethane, silicone, latex, polyglycolic lactic acid or other biodegradable polymer, especially one that is a hydrophilic, non-degrading polymer such as a hydrophilic polyurethane, for example TECOPHILIC which is made by Thermedics.
- a hydrophilic polyurethane for example TECOPHILIC which is made by Thermedics.
- Use of antimicrobial agents in hydrophilic materials is also described in an application filed on even date herewith, assigned attorney docket number 1985/0E556 and entitled "Antibiotic Hydrophilic Polymer Coating".
- the inorganic antimicrobial agent mixed with the coating material is one of the type discussed above and the concentration of the agent in the dry coating material is 0.01 to 50%, preferably 0.1 to 20% and most preferably from 0.5 to 10%.
- the resulting fabric made either by applying the inorganic agent to an adherent coating material, or as part of a mixture with the coating material by spraying or dipping, is a piece of fabric that is antimicrobial, pliable and porous.
- a preferred embodiment of the fabric of the invention utilized the following: fiber material: polyester silicone mixture: 50% o RTV and 50% xylene thickness of silicone layer: 1-5 microns agent particle size: 1-2.5 microns agent dispersal factor: 1% air pressure: 60 psi
- the antibiotic properties of the antibiotic zeolite particles of the invention may be assayed while in aqueous formulations using conventional assay techniques, including for example determining the minimum growth inhibitory concentration (MIC) with respect to a variety of bacteria, eumycetes and yeast.
- MIC minimum growth inhibitory concentration
- the assay for determining MIC can be carried out by smearing a solution containing bacteria for inoculation onto a plate culture medium to which a test sample of the encapsulated antibiotic zeolite particles is added in a particular concentration, followed by incubation and culturing of the plate.
- the MIC is defined as a minimum concentration thereof required for inhibiting the growth of each bacteria.
- the antibiotic zeolites are exceptionally suitable under relevant toxicity and biocompatibility standards for use in the fabric.
- the blend of the inorganic antimicrobial and elastomeric coating material is kneaded into the fabric. The kneading takes place without the fabric being held under tension. The blend coats the fabric fibers and fills the pores. The resulting fabric is fully coated with the antimicrobial agent.
- the fibers are either of a plurality of the mono-filament type, such as of a plurality of polyester filaments, formed in bundles, such as by twisting, or of a naturally multi-filament type, such as cotton.
- the object is that the fibers themselves have spaces, gaps or voids into which the antimicrobial agent can be placed.
- a dough or slurry of the antimicrobial agent is kneaded into a fabric of this type and the agent will be embedded in the spaces of the bundle of the plurality of mono-filaments forming a fiber or the fiber of natural material.
- the fabric can be made porous by holding it under tension and blowing out the agent from the pores, as described above. It can be left non-porous by permitting the agent to dry without attempting to remove the particles from the pores.
- a piece of the fabric of any of the types described above is cut to size and rolled into a generally tubular shape of the required diameter.
- the edges of the tube are joined together, such as by stitching with sutures or using an acceptable adhesive.
- some of the coating materials described above have thermosetting properties which would permit joining of the graft tube edges by heat sealing.
- the fabric forming the graft is of the fully coated type, it may be desired to coat it with a tissue compatible material such as collagen.
- a tissue compatible material such as collagen. This can be accomplished by coating one side of the fabric, to be the outer surface of the graft, with the collagen either before or after the graft is formed. Both surfaces can be coated wit the collagen.
- the collagen coating can be accomplished by spraying, painting, etc.
- the fabric can be dipped in a collagen solution either before of after the graft is formed.
- Example 1 A 1 " x 1 " sample of knitted polyester, available from Bard Vascular Systems
- Example 2 A Dow Shaker Test was performed on the polyester sample prepared in Example 1 (hereafter referred to as Sample A) to determine its inhibitory effect against S. aureus.
- the Dow Shaker Test is based on Dow Corporate Test Method 0923 for testing aerobic bacteria by Dow Chemical.
- the Dow Shaker Test is described below. Sample A was sterilized at 121 °C for 15 minutes.
- a culture tube containing S. aureus was prepared by adding one disk of S. aureus to the culture tube. From about 2 to 5 ml of broth was added to the culture tube.
- the culture tube was agitated with a vortex mixer until the disk was completely dissolved in the broth.
- the bacte ⁇ a in the culture tube were incubated for at least 3 hours at 35 °C.
- the culture tube was then refrigerated at about 2-8 °C until needed for testing.
- a 5 ml sample of bacteria from the culture tube was removed and agitated in a vortex mixer.
- the absorbance of the sample was measured at 475 nm with a spectrophotometer relative to the absorbance of the aforementioned broth.
- Broth and/or bacteria from the culture tube were added to the sample until an absorbance of about 0.1 absorbance units was obtained. This corresponded to from about 10 5 to about 10 6 colony forming units per milliliter (CFU/ml).
- 5 ml of suspension was extracted from the sample and added to a flask containing 70 ml of sterile buffer.
- the resulting solution contained from about 10 4 to about 10 5 CFU/ml.
- the flask was capped and shaken on a wrist action shaker for 1 minute at maximum speed. This is referred to as time "0 hours" below.
- the number of colony forming units in 1ml of the solution was determined at time 0 hours by the following procedure. 1 ml of solution was extracted from the flask and added to a vial containing 9 ml of buffer solution to form a 10:1 dilution. The solution was repeatedly diluted with buffer solution until a plate count of about 30 to about 200 CFU/ml was obtained. 1 ml of the solution from the flask and each dilution were transferred to separate petri dishes. About 15-20 ml molten agar was added to each dish. Each dish was rotated 10 times clockwise and 10 times counter-clockwise to evenly distribute the agar and bacteria. Then, each dish was incubated for 18-24 hours at 35 °C. A plate count was performed on the petri dish containing from about 30 to about 200 bacteria colony forming units to determine the number of colony forming units.
- sample A was added to the flask and shaken with a wrist action shaker for 1 hour.
- the number of colony forming units in 1 ml of the solution in the flask was determined by the procedure above using 2 petri dishes. If the numbers of colony forming units in the 2 petri dishes were not within 15%> of each other, the entire Dow Shaker Test was repeated.
- the number of colony forming units in 1 ml of the solution was also determined after shaking the flask with a wrist action shaker for 18 and 24 hours.
- a control was tested by the same procedure as sample A.
- the control was a 1 " x 1 " sample of knitted polyester, available from Bard Vascular Systems Division as knitted polyester style no. 6103.
- the number of colony forming units at times 0 hours, 1 hour, 18 hours, and 24 hours for sample A and the control are shown in Table 1.
- the percentage of bacteria killed by sample A and the control at times 1 hour, 18 hours, and 24 hours are shown in Table 2.
- Sample A exhibited 99.53%) inhibition of S. aureus after 24 hours of contact with the bacteria.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99971220A EP1133326A2 (en) | 1998-11-23 | 1999-11-16 | Antimicrobial fabric and medical graft of the fabric |
AU35805/00A AU3580500A (en) | 1998-11-23 | 1999-11-16 | Antimicrobial fabric and medical graft of the fabric |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/197,809 US6296863B1 (en) | 1998-11-23 | 1998-11-23 | Antimicrobial fabric and medical graft of the fabric |
US09/197,809 | 1998-11-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000032247A2 WO2000032247A2 (en) | 2000-06-08 |
WO2000032247A3 WO2000032247A3 (en) | 2000-10-05 |
WO2000032247A9 true WO2000032247A9 (en) | 2001-03-08 |
Family
ID=22730853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/027190 WO2000032247A2 (en) | 1998-11-23 | 1999-11-16 | Antimicrobial fabric and medical graft of the fabric |
Country Status (4)
Country | Link |
---|---|
US (1) | US6296863B1 (en) |
EP (1) | EP1133326A2 (en) |
AU (1) | AU3580500A (en) |
WO (1) | WO2000032247A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8834520B2 (en) | 2007-10-10 | 2014-09-16 | Wake Forest University | Devices and methods for treating spinal cord tissue |
US9289193B2 (en) | 2008-07-18 | 2016-03-22 | Wake Forest University Health Sciences | Apparatus and method for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage |
US9737455B2 (en) | 2007-01-10 | 2017-08-22 | Wake Forest Univeristy Health Sciences | Apparatus and method for wound treatment employing periodic sub-atmospheric pressure |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7500988B1 (en) * | 2000-11-16 | 2009-03-10 | Cordis Corporation | Stent for use in a stent graft |
US6887268B2 (en) * | 1998-03-30 | 2005-05-03 | Cordis Corporation | Extension prosthesis for an arterial repair |
US6585767B1 (en) * | 1998-11-23 | 2003-07-01 | Agion Technologies, Inc. | Antimicrobial suturing ring for heart valve |
US20010023355A1 (en) * | 1999-03-08 | 2001-09-20 | Steve Danno | Ear piercing healing grommet system |
ATE400315T1 (en) | 1999-11-29 | 2008-07-15 | Hill Rom Services Inc | DEVICE FOR TREATING A WOUND |
US7179849B2 (en) * | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
CA2411944C (en) * | 2000-06-09 | 2010-12-14 | Baylor College Of Medicine | The combination of antimicrobial agents and bacterial interference to coat medical devices |
WO2002018003A1 (en) * | 2000-08-30 | 2002-03-07 | Biocoat Incorporated | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties |
US6685681B2 (en) | 2000-11-29 | 2004-02-03 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
US6855135B2 (en) | 2000-11-29 | 2005-02-15 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
US20030031728A1 (en) * | 2001-08-09 | 2003-02-13 | Martin Daniel H. | Antimicrobial polymeric tubing |
MXPA04005332A (en) * | 2001-12-03 | 2005-05-16 | Bard Inc C R | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same. |
US7357949B2 (en) * | 2001-12-21 | 2008-04-15 | Agion Technologies Inc. | Encapsulated inorganic antimicrobial additive for controlled release |
US20040077747A1 (en) * | 2002-02-05 | 2004-04-22 | Payne Stephen A. | Antimicrobial superfinish and method of making |
US20030159200A1 (en) * | 2002-02-28 | 2003-08-28 | Don Elrod | Antimicrobial fabrics through surface modification |
US20030200980A1 (en) * | 2002-04-29 | 2003-10-30 | Legassie Raymond P. | Mascara brush with antibacterial bristle fibers |
CA2495385A1 (en) | 2002-08-21 | 2004-03-04 | Hill-Rom Services, Inc. | Wound packing for preventing wound closure |
US7520872B2 (en) * | 2002-09-13 | 2009-04-21 | Neogen Technologies, Inc. | Closed wound drainage system |
DE10243132B4 (en) | 2002-09-17 | 2006-09-14 | Biocer Entwicklungs Gmbh | Anti-infective, biocompatible titanium oxide coatings for implants and methods of making them |
US7641912B1 (en) | 2003-01-13 | 2010-01-05 | EnviroCare Corporation | Antimicrobial coatings for treatment of surfaces in a building setting and method of applying same |
US8282951B2 (en) | 2003-01-13 | 2012-10-09 | EnviroCare Corporation | Antimicrobial coatings for treatment of surfaces in a building setting and method of applying same |
TWI347300B (en) * | 2003-01-20 | 2011-08-21 | Toagosei Co Ltd | Antibacterial composition and ant1bacterial products |
US20040186528A1 (en) * | 2003-03-20 | 2004-09-23 | Medtronic, Inc. | Subcutaneous implantable medical devices with anti-microbial agents for chronic release |
US6890161B2 (en) * | 2003-03-31 | 2005-05-10 | Assistive Technology Products, Inc. | Disposable fluid delivery system |
DE10323676A1 (en) * | 2003-05-15 | 2004-12-02 | Aesculap Ag & Co. Kg | Implant with long-term antibiotic effect |
DE10326443A1 (en) * | 2003-06-10 | 2005-02-03 | Katz International Coasters Gmbh & Co. Kg | Use of zeolite filled pulp plates for odor and moisture adsorption |
US7578460B2 (en) * | 2003-06-17 | 2009-08-25 | Emerson Electric Co. | Food waste disposer having antimicrobial components |
US20060259020A1 (en) * | 2003-09-17 | 2006-11-16 | Minnesota Scientific, Inc. | Bacteria resistant coating for surgical instrument |
US20050058682A1 (en) * | 2003-09-17 | 2005-03-17 | Minnesota Scientific, Inc. | Bacteria resistant coating for surgical instrument |
WO2005037296A1 (en) * | 2003-10-16 | 2005-04-28 | Toagosei Co., Ltd. | Anti-coronavirus agent |
US8012192B2 (en) * | 2004-02-18 | 2011-09-06 | Boston Scientific Scimed, Inc. | Multi-stent delivery system |
US7335613B2 (en) * | 2004-04-08 | 2008-02-26 | Rohm And Haas Company | Fiber substrate with antibacterial finish and methods of making and using the same |
WO2005108548A2 (en) * | 2004-05-05 | 2005-11-17 | Translogic Corporation | Anti-microbial carrier systems |
US20050255230A1 (en) * | 2004-05-17 | 2005-11-17 | Clerc Claude O | Method of manufacturing a covered stent |
US7794490B2 (en) * | 2004-06-22 | 2010-09-14 | Boston Scientific Scimed, Inc. | Implantable medical devices with antimicrobial and biodegradable matrices |
US20060009839A1 (en) * | 2004-07-12 | 2006-01-12 | Scimed Life Systems, Inc. | Composite vascular graft including bioactive agent coating and biodegradable sheath |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
US20060068024A1 (en) * | 2004-09-27 | 2006-03-30 | Schroeder Kurt M | Antimicrobial silver halide composition |
DE102004052203A1 (en) * | 2004-10-20 | 2006-05-04 | Aesculap Ag & Co. Kg | Reabsorbable carrier material, useful e.g. in medicinal-technical product and in the human or animal body, comprises silver particles |
US20060126751A1 (en) * | 2004-12-10 | 2006-06-15 | Anthony Bessios | Technique for disparity bounding coding in a multi-level signaling system |
US20060252326A1 (en) * | 2005-05-03 | 2006-11-09 | Mishler Amy M | Antimicrobial cubicle curtain and methods of making the same |
US20070141106A1 (en) * | 2005-10-19 | 2007-06-21 | Bonutti Peter M | Drug eluting implant |
WO2007070649A2 (en) | 2005-12-14 | 2007-06-21 | 3M Innovative Properties Company | Antimicrobial coating system |
US9247736B2 (en) | 2005-12-14 | 2016-02-02 | 3M Innovative Properties Company | Antimicrobial adhesive films |
US20070154507A1 (en) * | 2005-12-30 | 2007-07-05 | Patton David L | Antimicrobial agent to inhibit the growth of microorganism on clothing |
US20070154505A1 (en) * | 2005-12-30 | 2007-07-05 | Manico Joseph A | Antimicrobial agent to inhibit the growth of microorganisms on building materials |
US20070154506A1 (en) * | 2005-12-30 | 2007-07-05 | Patton David L | Antimicrobial agent to inhibit the growth of microorganisms on disposable products |
US20070154508A1 (en) * | 2005-12-30 | 2007-07-05 | Patton David L | Antimicrobial agent to inhibit the growth of microorganisms on outerwear used in the medical profession |
US20070166344A1 (en) * | 2006-01-18 | 2007-07-19 | Xin Qu | Non-leaching surface-active film compositions for microbial adhesion prevention |
US20070243258A1 (en) * | 2006-04-13 | 2007-10-18 | 3M Innovative Properties Company | Method and apparatus for forming crosslinked chromonic nanoparticles |
US20070275472A1 (en) * | 2006-05-23 | 2007-11-29 | Eastman Kodak Company | Method for detecting presence of silver-containing antimicrobial agents |
KR100805772B1 (en) | 2006-08-16 | 2008-02-21 | 김택영 | Antimicrobial Gauze and the Manufacture method |
US7931651B2 (en) | 2006-11-17 | 2011-04-26 | Wake Lake University Health Sciences | External fixation assembly and method of use |
US7754625B2 (en) * | 2006-12-22 | 2010-07-13 | Aglon Technologies, Inc. | Wash-durable and color stable antimicrobial treated textiles |
KR101719081B1 (en) | 2007-01-30 | 2017-03-22 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Bioerodible wraps and uses therefor |
US20090041727A1 (en) * | 2007-08-08 | 2009-02-12 | Conjugon, Inc. | Compositions and Methods for Microbe Storage and Delivery |
BRPI0820704A2 (en) * | 2007-12-12 | 2015-06-16 | 3M Innovative Proferties Company | Manufacturing Methods of Molded Polymeric Materials |
US20100050197A1 (en) * | 2008-07-25 | 2010-02-25 | Disctekk, Llc | Optical card |
JP5345703B2 (en) * | 2008-12-24 | 2013-11-20 | ケーシーアイ ライセンシング インコーポレイテッド | Membrane, system, and method for applying reduced pressure to a subcutaneous tissue site |
US20100175627A1 (en) * | 2009-01-09 | 2010-07-15 | Carpenter James R | Wild animal care devices having an antimicrobial agent |
US8685424B2 (en) | 2010-10-14 | 2014-04-01 | Zeus Industrial Products, Inc. | Antimicrobial substrate |
CA2778459C (en) | 2009-10-28 | 2016-08-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Bioerodible wraps and uses therefor |
CN102802685B (en) * | 2009-11-25 | 2015-05-27 | 扩散技术公司 | Post-charging of zeolite doped plastics with antimicrobial metal ions |
RU2526168C2 (en) | 2009-12-11 | 2014-08-20 | Дифьюжн Текнолоджиз, Инк. | Method for making antimicrobial implants of polyetheretherketone |
WO2011084559A2 (en) * | 2009-12-16 | 2011-07-14 | Neograft Technologies, Inc. | Graft devices and methods of use |
WO2011082295A2 (en) | 2009-12-31 | 2011-07-07 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
BR112012026636B1 (en) | 2010-05-07 | 2019-01-15 | Difusion Technologies, Inc. | Increased hydrophilicity medical implants and method to minimize biofilm formation in a patient |
EP2595695B1 (en) | 2010-07-19 | 2019-02-06 | Neograft Technologies, Inc. | Graft devices and methods of use |
US9155310B2 (en) | 2011-05-24 | 2015-10-13 | Agienic, Inc. | Antimicrobial compositions for use in products for petroleum extraction, personal care, wound care and other applications |
EP2713747B1 (en) | 2011-05-24 | 2023-02-22 | Agienic, Inc. | Compositions and methods for antimicrobial metal nanoparticles |
US9579224B2 (en) | 2011-07-25 | 2017-02-28 | Neograft Technologies, Inc. | Vessel remodeling methods and devices for use in a graft device |
US10064273B2 (en) | 2015-10-20 | 2018-08-28 | MR Label Company | Antimicrobial copper sheet overlays and related methods for making and using |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525510A (en) | 1980-01-10 | 1985-06-25 | Desoto, Inc. | Thermosetting latex coating compositions produced by copolymerization in aqueous emulsion in the presence of water-insoluble polyhydric alcohol |
JPS5937956A (en) | 1982-08-24 | 1984-03-01 | カネボウ株式会社 | Particle filled fiber structure |
JPS59133235A (en) | 1983-01-21 | 1984-07-31 | Kanebo Ltd | Zeolite particle-containing polymer and its production |
GB8616294D0 (en) * | 1986-07-03 | 1986-08-13 | Johnson Matthey Plc | Antimicrobial compositions |
US4938958A (en) | 1986-12-05 | 1990-07-03 | Shinagawa Fuel Co., Ltd. | Antibiotic zeolite |
JPS63265958A (en) | 1987-04-22 | 1988-11-02 | Shinagawa Nenryo Kk | Antibacterial resin composition |
JPH0618899B2 (en) | 1987-06-30 | 1994-03-16 | 品川燃料株式会社 | Film containing antibacterial zeolite |
JPH0741061B2 (en) | 1987-07-09 | 1995-05-10 | 華郎 前田 | Medical dressing |
JPS6415056A (en) | 1987-07-09 | 1989-01-19 | Hanarou Maeda | Body indwelling tube |
JPH0688885B2 (en) | 1987-12-26 | 1994-11-09 | 品川燃料株式会社 | Method for producing dispersion containing antibacterial powder |
US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US5009898A (en) | 1988-09-29 | 1991-04-23 | Kabushiki Kaisha Sangi | Antimicrobial hydroxyapatite powders and methods for preparing them |
US5207706A (en) * | 1988-10-05 | 1993-05-04 | Menaker M D Gerald | Method and means for gold-coating implantable intravascular devices |
JPH03199403A (en) | 1989-12-27 | 1991-08-30 | Chugoku Pearl Hanbai Kk | Aseptic glove |
JPH0639368B2 (en) | 1990-02-28 | 1994-05-25 | 株式会社萩原技研 | Antibacterial organism based on silica gel |
CA2020482C (en) | 1990-07-05 | 1999-10-12 | Sellathurai Suppiah | Supported high silica zeolites |
US5102401A (en) | 1990-08-22 | 1992-04-07 | Becton, Dickinson And Company | Expandable catheter having hydrophobic surface |
US5296238A (en) | 1991-02-26 | 1994-03-22 | Toagosei Chemical Industry Co., Inc. | Microbicides |
US5282847A (en) | 1991-02-28 | 1994-02-01 | Medtronic, Inc. | Prosthetic vascular grafts with a pleated structure |
US5520664A (en) | 1991-03-01 | 1996-05-28 | Spire Corporation | Catheter having a long-lasting antimicrobial surface treatment |
US5180585A (en) | 1991-08-09 | 1993-01-19 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
WO1993007924A1 (en) | 1991-10-18 | 1993-04-29 | Spire Corporation | Bactericidal coatings for implants |
JP2939036B2 (en) | 1991-12-04 | 1999-08-25 | 鐘紡株式会社 | Non-woven bandage for cast bottom winding |
US5305827A (en) | 1992-03-04 | 1994-04-26 | United Technologies Corporation | Antimicrobial hydrophilic coating |
US5681575A (en) | 1992-05-19 | 1997-10-28 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
EP0597097A4 (en) | 1992-05-20 | 1995-07-05 | Hachiku Shoji Kk | Device for preparing long preservable box-lunch and lunch box therefor. |
JP3448896B2 (en) | 1992-05-21 | 2003-09-22 | 東亞合成株式会社 | Manufacturing method of antibacterial agent |
US5492763A (en) | 1992-06-08 | 1996-02-20 | Spire Corporation | Infection resistant medical devices and process |
JP3201023B2 (en) | 1992-11-17 | 2001-08-20 | 東亞合成株式会社 | Manufacturing method of antibacterial synthetic fiber |
JPH0896B2 (en) | 1993-02-16 | 1996-01-10 | 株式会社ダイキョー | Antibacterial cutting board manufacturing method |
US5429628A (en) | 1993-03-31 | 1995-07-04 | The Procter & Gamble Company | Articles containing small particle size cyclodextrin for odor control |
DE4425278A1 (en) | 1994-07-16 | 1996-01-18 | Basf Ag | Mixtures containing silver on non-zeolitic carrier oxides |
JP4235849B2 (en) | 1994-07-19 | 2009-03-11 | シナネン株式会社 | Deodorant cosmetic with excellent discoloration resistance and dispersibility |
US5509899A (en) | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
-
1998
- 1998-11-23 US US09/197,809 patent/US6296863B1/en not_active Expired - Lifetime
-
1999
- 1999-11-16 AU AU35805/00A patent/AU3580500A/en not_active Abandoned
- 1999-11-16 EP EP99971220A patent/EP1133326A2/en not_active Withdrawn
- 1999-11-16 WO PCT/US1999/027190 patent/WO2000032247A2/en active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737455B2 (en) | 2007-01-10 | 2017-08-22 | Wake Forest Univeristy Health Sciences | Apparatus and method for wound treatment employing periodic sub-atmospheric pressure |
US8834520B2 (en) | 2007-10-10 | 2014-09-16 | Wake Forest University | Devices and methods for treating spinal cord tissue |
US9289193B2 (en) | 2008-07-18 | 2016-03-22 | Wake Forest University Health Sciences | Apparatus and method for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage |
Also Published As
Publication number | Publication date |
---|---|
AU3580500A (en) | 2000-06-19 |
WO2000032247A2 (en) | 2000-06-08 |
US6296863B1 (en) | 2001-10-02 |
EP1133326A2 (en) | 2001-09-19 |
WO2000032247A3 (en) | 2000-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6296863B1 (en) | Antimicrobial fabric and medical graft of the fabric | |
US6585767B1 (en) | Antimicrobial suturing ring for heart valve | |
US6582715B1 (en) | Antimicrobial orthopedic implants | |
US6436422B1 (en) | Antibiotic hydrophilic polymer coating | |
US6866859B2 (en) | Bi-laminar, hyaluronan coatings with silver-based anti-microbial properties | |
Sjollema et al. | In vitro methods for the evaluation of antimicrobial surface designs | |
AU616472B2 (en) | Infection-resistant compositions, medical devices and surfaces and method for preparing and using same | |
US6645483B2 (en) | Lubricious coating | |
JP2006503647A (en) | Medical care material holding antibacterial agent | |
US20080268011A1 (en) | Antimicrobial Implant with a Flexible Porous Structure | |
WO2000064506A1 (en) | Stent having antimicrobial agent | |
WO2001037789A1 (en) | Antimicrobial dental products | |
JPS6211457A (en) | Production of infection resistant polymer material | |
US6905711B1 (en) | Antimicrobial agents, products incorporating said agents and methods of making products incorporating antimicrobial agents | |
EP1124743B1 (en) | Belt having antimicrobial action | |
AU2002246277B2 (en) | Lubricious coating comprising pharmacological additives | |
WO2014138885A1 (en) | Polymeric coatings having antimicrobial properties | |
AU2002246277A1 (en) | Lubricious coating comprising pharmacological additives | |
WO2001037670A2 (en) | Antimicrobial hook and loop fastener | |
Vigo | Advances in antimicrobial polymers and materials | |
WO2000014284A9 (en) | Antimicrobial footwear and process of manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999971220 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999971220 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |